AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33427173 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged deprivation
Number of subjects: 0
Study 34705137 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Botulinum toxin injection (50 U) administered 1 week before surgery
Number of subjects: 62
Study 34705137 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Botulinum toxin injection
Number of subjects: 62
Study 32429708 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-day CBTI workshop
Number of subjects: 210
Study 32429708 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help Internet-delivered CBTI
Number of subjects: 210
Study 32429708 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-day SHE workshop
Number of subjects: 210
Study 33306999 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 419
Study 33306999 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube
Number of subjects: 419
Study 33306999 — intervention group
Group type: COMPARATOR
Intervention: IRIS Registry
Number of subjects: 419
Study 33306999 — intervention group
Group type: COMPARATOR
Intervention: RCT
Number of subjects: 419
Study 35732572 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinence training with urotherapy
Number of subjects: 21
Study 35732572 — intervention group
Group type: COMPARATOR
Intervention: Typically developing children (control group)
Number of subjects: 21
Study 32493125 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies and decision making
Number of subjects: 20
Study 32493125 — intervention group
Group type: EXPERIMENTAL
Intervention: Importance of recruiters
Number of subjects: 20
Study 32493125 — intervention group
Group type: EXPERIMENTAL
Intervention: Research governance demands
Number of subjects: 20
Study 34328630 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mcg ropeginterferon alfa-2b
Number of subjects: 40
Study 34328630 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mcg ropeginterferon alfa-2b
Number of subjects: 40
Study 34328630 — intervention group
Group type: EXPERIMENTAL
Intervention: 270 mcg ropeginterferon alfa-2b
Number of subjects: 40
Study 34328630 — intervention group
Group type: COMPARATOR
Intervention: peg-IFN alfa-2a
Number of subjects: 40
Study 34328630 — intervention group
Group type: EXPERIMENTAL
Intervention: ropeginterferon alfa-2b (all doses)
Number of subjects: 40
Study 33975525 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 2
Study 33975525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 36181085 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (target train‐of‐four 0 and posttetanic count ≥ 1)
Number of subjects: 72
Study 36181085 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (target train‐of‐four count 1‐3)
Number of subjects: 72
Study 36181085 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Number of subjects: 72
Study 36181085 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade
Number of subjects: 72
Study 32098542 — intervention group
Group type: EXPERIMENTAL
Intervention: Local vibrations (100 Hz)
Number of subjects: 10
Study 32098542 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 10
Study 33033021 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral feeding formula (1.5 kcal/mL, 54% carbohydrate)
Number of subjects: 0
Study 33033021 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower carbohydrate isocaloric enteral feeding formula (1.5 kcal/mL, 28% carbohydrate)
Number of subjects: 0
Study 36660970 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics and Zinc (Group 4)
Number of subjects: 132
Study 36660970 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Group 2)
Number of subjects: 132
Study 36660970 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (Group 3)
Number of subjects: 132
Study 36660970 — intervention group
Group type: COMPARATOR
Intervention: Dietary recommendations (Control Group 1)
Number of subjects: 132
Study 33413338 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional identity formation-oriented intervention format (3 sessions in the first half for Group A)
Number of subjects: 112
Study 33413338 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional identity formation-oriented intervention format (3 sessions in the second half for Group B)
Number of subjects: 112
Study 33413338 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 112
Study 32925342 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder roll (2-inch vertical)
Number of subjects: 20
Study 32925342 — intervention group
Group type: COMPARATOR
Intervention: No shoulder roll
Number of subjects: 20
Study 33517517 — intervention group
Group type: EXPERIMENTAL
Intervention: PSFON (point‐spread‐function modelling)
Number of subjects: 12
Study 33517517 — intervention group
Group type: COMPARATOR
Intervention: PSFOFF (without point‐spread‐function modelling)
Number of subjects: 12
Study 32632173 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb loading (LLL) exercise with augmented loading feedback
Number of subjects: 30
Study 32632173 — intervention group
Group type: COMPARATOR
Intervention: Lower limb loading (LLL) exercise without augmented loading feedback
Number of subjects: 30
Study 35125128 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and physical activity best practices
Number of subjects: 49
Study 35125128 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition self-efficacy
Number of subjects: 49
Study 35125128 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of food program best practices
Number of subjects: 49
Study 35125128 — intervention group
Group type: COMPARATOR
Intervention: Self-efficacy in family style meal service
Number of subjects: 49
Study 35125128 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and physical activity scores
Number of subjects: 49
Study 34291444 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention (Bobath concept)
Number of subjects: 74
Study 34291444 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physiotherapy)
Number of subjects: 74
Study 34291444 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of physiotherapy sessions
Number of subjects: 74
Study 34291444 — intervention group
Group type: EXPERIMENTAL
Intervention: Home activities performed by parents
Number of subjects: 74
Study 35810754 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib (group A) administered orally at 160 mg twice per day for 28-day cycles.
Number of subjects: 590
Study 35810754 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine-rituximab (group B) with bendamustine at 90 mg/m2 on days 1 and 2 for six cycles plus rituximab at 375 mg/m2 on day 1 of cycle 1 and 500 mg/m2 on day 1 of cycles 2–6, administered intravenously.
Number of subjects: 590
Study 35810754 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib (group C) for patients with del(17)(p13·1).
Number of subjects: 590
Study 35810754 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib (group A)
Number of subjects: 590
Study 35810754 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine-rituximab (group B)
Number of subjects: 590
Study 33957649 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream applied to the cervix weekly for 12 weeks
Number of subjects: 90
Study 33957649 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment prior to LEEP)
Number of subjects: 90
Study 32519431 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation intervention
Number of subjects: 43
Study 32519431 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 43
Study 34454442 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin for 12 weeks
Number of subjects: 13
Study 33021583 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrupedal Movement Training (QMT)
Number of subjects: 42
Study 33021583 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 42
Study 34048817 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-SBRT 34 Gy
Number of subjects: 229
Study 34048817 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-SBRT 30 Gy
Number of subjects: 229
Study 32299852 — intervention group
Group type: COMPARATOR
Intervention: PR only
Number of subjects: 34
Study 32299852 — intervention group
Group type: COMPARATOR
Intervention: PR+SMS
Number of subjects: 34
Study 32299852 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 34
Study 33878154 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) 50 mg every 4 weeks during the OLE
Number of subjects: 198
Study 33878154 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) followed by Golimumab (GLM) 50 mg every 4 weeks during the OLE
Number of subjects: 198
Study 35820904 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise intervention
Number of subjects: 18
Study 35820904 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser needle acupuncture treatment
Number of subjects: 18
Study 34282645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) integrated with activity pacing for 6 sessions by a trained oncology nurse
Number of subjects: 58
Study 34282645 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 58
Study 32818112 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral BI 1026706 100 mg twice daily for 12 weeks
Number of subjects: 105
Study 32818112 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 105
Study 34753304 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 264
Study 34753304 — intervention group
Group type: COMPARATOR
Intervention: Endovascular treatment (EVT) in BASICS trial centers
Number of subjects: 264
Study 32415231 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy protocol based on Pivotal Response Treatment (PRT)
Number of subjects: 0
Study 35452104 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody postexposure prophylaxis (PEP) with casirivimab and imdevimab
Number of subjects: 0
Study 35452104 — intervention group
Group type: COMPARATOR
Intervention: No monoclonal antibody postexposure prophylaxis (PEP)
Number of subjects: 0
Study 33937162 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of monthly attendance fees for full-day kindergartens
Number of subjects: 236
Study 33937162 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence generated from the RCT
Number of subjects: 236
Study 32912410 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal monitoring treatment group
Number of subjects: 104
Study 32912410 — intervention group
Group type: COMPARATOR
Intervention: Routine monitoring treatment group
Number of subjects: 104
Study 36056385 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART cognitive rehabilitation programme
Number of subjects: 0
Study 32593257 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy + audiovisual correction
Number of subjects: 89
Study 32593257 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy + audiovisual correction + testosterone undecanoate
Number of subjects: 89
Study 32593257 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy and escitalopram / tofisopam
Number of subjects: 89
Study 34358777 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2, oral prednisone 5 mg twice daily, and oral enzalutamide 160 mg/d (arm DE)
Number of subjects: 246
Study 34358777 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 and oral prednisone 5 mg twice daily (arm D)
Number of subjects: 246
Study 33463883 — intervention group
Group type: EXPERIMENTAL
Intervention: Purchasing pesticides for self-poisoning (cases)
Number of subjects: 250
Study 36457354 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal Functional Electrical Stimulation (FES)
Number of subjects: 80
Study 34614266 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% oxygen
Number of subjects: 54
Study 34614266 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 54
Study 34614266 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 54
Study 35640438 — intervention group
Group type: EXPERIMENTAL
Intervention: Kegel exercise
Number of subjects: 150
Study 35640438 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubricant gel
Number of subjects: 150
Study 35640438 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 34871892 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward Walking on Sand (SG)
Number of subjects: 28
Study 34871892 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward Walking on Sand (SG)
Number of subjects: 28
Study 34871892 — intervention group
Group type: COMPARATOR
Intervention: Forward Walking on Overground (OG)
Number of subjects: 28
Study 34871892 — intervention group
Group type: COMPARATOR
Intervention: Backward Walking on Overground (OG)
Number of subjects: 28
Study 32204151 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge acquired from teachers about menstruation and cleaning menstrual pads
Number of subjects: 6
Study 32204151 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative thoughts and fears related to menstrual hygiene
Number of subjects: 6
Study 32204151 — intervention group
Group type: EXPERIMENTAL
Intervention: Myths and beliefs about menstruation
Number of subjects: 6
Study 32204151 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional responses related to menstrual self hygiene
Number of subjects: 6
Study 32204151 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial and physical disadvantages
Number of subjects: 6
Study 34033270 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin, uptitrated to 16 mg/d
Number of subjects: 100
Study 33065103 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 280
Study 33065103 — intervention group
Group type: COMPARATOR
Intervention: Control (no ivermectin)
Number of subjects: 280
Study 34489350 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Protective Equipment (PPE)
Number of subjects: 48
Study 33214044 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) to prostate and pelvis, dose delivered was 35–37.5 Gy to prostate and gross node, 25 Gy in five fractions to elective pelvic nodal region.
Number of subjects: 60
Study 35838816 — intervention group
Group type: EXPERIMENTAL
Intervention: BPEC (Behavioral Parent Emotion Coaching)
Number of subjects: 119
Study 35838816 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 119
Study 33347530 — intervention group
Group type: EXPERIMENTAL
Intervention: injectable platelet‐rich fibrin (i‐PRF)
Number of subjects: 40
Study 33347530 — intervention group
Group type: COMPARATOR
Intervention: Control group (no i‐PRF)
Number of subjects: 40
Study 35626906 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group
Number of subjects: 113
Study 35626906 — intervention group
Group type: COMPARATOR
Intervention: Photo group
Number of subjects: 113
Study 35626906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 113
Study 32084505 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 62
Study 32084505 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 62
Study 35301388 — intervention group
Group type: EXPERIMENTAL
Intervention: high-definition tRNS
Number of subjects: 61
Study 35301388 — intervention group
Group type: COMPARATOR
Intervention: simple-definition tRNS
Number of subjects: 61
Study 35301388 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 61
Study 33999161 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 vs 6 months of androgen deprivation therapy (ADT) with external beam radiotherapy in DFCI 95‐096 trial
Number of subjects: 1173
Study 33999161 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 vs 36 months of ADT with external beam radiotherapy in EORTC 22961 trial
Number of subjects: 1173
Study 33999161 — intervention group
Group type: COMPARATOR
Intervention: PSA failure in EORTC 22961
Number of subjects: 1173
Study 32555938 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone foam implants (Lifesil®)
Number of subjects: 58
Study 32555938 — intervention group
Group type: COMPARATOR
Intervention: Microtexturized silicone implants (Lifesil®)
Number of subjects: 58
Study 36213584 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Number of subjects: 500
Study 36213584 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercises combined with acupuncture therapy
Number of subjects: 500
Study 33360345 — intervention group
Group type: EXPERIMENTAL
Intervention: SMDS combined with aspirin
Number of subjects: 135
Study 32163097 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 5) plus Pemetrexed (500 mg/m2) followed by maintenance Pemetrexed (500 mg/m2) every 3 weeks
Number of subjects: 433
Study 32163097 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel monotherapy (60 mg/m2) every 3 weeks
Number of subjects: 433
Study 35514254 — intervention group
Group type: COMPARATOR
Intervention: Test linagliptin formulation (5 mg) under fasting conditions
Number of subjects: 84
Study 35514254 — intervention group
Group type: COMPARATOR
Intervention: Reference linagliptin formulation (5 mg) under fasting conditions
Number of subjects: 84
Study 35514254 — intervention group
Group type: COMPARATOR
Intervention: Test linagliptin formulation (5 mg) under fed conditions
Number of subjects: 84
Study 35514254 — intervention group
Group type: COMPARATOR
Intervention: Reference linagliptin formulation (5 mg) under fed conditions
Number of subjects: 84
Study 34795270 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (including vitamins, iron, and zinc)
Number of subjects: 80
Study 34795270 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (including vitamins and iron)
Number of subjects: 80
Study 34795270 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 80
Study 34795270 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 80
Study 34348455 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine 5x40 mg/m2 + PEG-ASP 2,500 IU/m2
Number of subjects: 143
Study 34348455 — intervention group
Group type: COMPARATOR
Intervention: High-dose cytarabine (HIDAC) 4x3g/m2 + PEG-ASP 2,500 IU/m2
Number of subjects: 143
Study 34348455 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine + PEG-ASP
Number of subjects: 143
Study 34348455 — intervention group
Group type: COMPARATOR
Intervention: High-dose cytarabine + PEG-ASP
Number of subjects: 143
Study 34245010 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 6380
Study 34245010 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 6380
Study 34245010 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal ASM selection
Number of subjects: 6380
Study 33374768 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccination uptake
Number of subjects: 286
Study 33374768 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-HBc positivity
Number of subjects: 286
Study 33374768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharps injuries (SIs)
Number of subjects: 286
Study 33374768 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency procedure exposures
Number of subjects: 286
Study 33374768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulance exposures
Number of subjects: 286
Study 33374768 — intervention group
Group type: EXPERIMENTAL
Intervention: Hollow-bore needle injuries
Number of subjects: 286
Study 33374768 — intervention group
Group type: EXPERIMENTAL
Intervention: Unreported SIs
Number of subjects: 286
Study 33374768 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle recapping
Number of subjects: 286
Study 33374768 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety engineered devices (SEDs) usage
Number of subjects: 286
Study 33374768 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge score
Number of subjects: 286
Study 33374768 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection-control training participation
Number of subjects: 286
Study 33374768 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of SIs for untrained paramedics
Number of subjects: 286
Study 36092992 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-GROW coaching intervention
Number of subjects: 109
Study 36092992 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 109
Study 33269553 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Oxygen Therapy (HFT)
Number of subjects: 30
Study 33269553 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive Ventilation (NIV)
Number of subjects: 30
Study 36471595 — intervention group
Group type: EXPERIMENTAL
Intervention: PRD + KAA (42 patients)
Number of subjects: 79
Study 36471595 — intervention group
Group type: COMPARATOR
Intervention: PRD (37 patients)
Number of subjects: 79
Study 36471595 — intervention group
Group type: EXPERIMENTAL
Intervention: PRD + KAA
Number of subjects: 79
Study 33353412 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tanning behavior change intervention
Number of subjects: 0
Study 33353412 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32979314 — intervention group
Group type: EXPERIMENTAL
Intervention: WONDFO SARS-CoV-2 Antibody Test (Wondfo Biotech, Guangzhou, China)
Number of subjects: 56000
Study 35029220 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 33079445 — intervention group
Group type: EXPERIMENTAL
Intervention: GPIbα (instrumented by cis-pQTL)
Number of subjects: 0
Study 33079445 — intervention group
Group type: EXPERIMENTAL
Intervention: GPIbα (instrumented by trans-pQTL)
Number of subjects: 0
Study 33079445 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet count
Number of subjects: 0
Study 33079445 — intervention group
Group type: COMPARATOR
Intervention: GPIbα (cis-pQTL)
Number of subjects: 0
Study 36897521 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Rosuvastatin fixed dose combination (10 mg/10 mg)
Number of subjects: 68